Non-steroidal mineralocorticoid receptor antagonists

Bibliography

• BRILLA CG, PICK R, TAN LB, JANICKI JS, WEBER KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. (1990) 67(6):1355-1364.
   PubMed Web of Science ®Google Scholar
• ROCHA R, RUDOLPH AE, FRIERDICH GE et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. (2002) 283(5):H1802-H1810.
   PubMed Web of Science ®Google Scholar
• NISHIZAKA MK, ZAMAN MA, GREEN SA, RENFROE KY, CALHOUN DA: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation (2004) 109(23):2857-2861.
   PubMed Web of Science ®Google Scholar
• HU X, LI S, MCMAHON EG, LALA DS, RUDOLPH AE: Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev. Med. Chem. (2005) 5(8):709-718.
   PubMed Web of Science ®Google Scholar
• WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15(8):709-716.
   PubMed Web of Science ®Google Scholar
• WHITE WB, CARR AA, KRAUSE S et al.: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. (2003) 92(1):38-42.
   PubMed Web of Science ®Google Scholar
• WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41(5):1021-1026.
   PubMed Web of Science ®Google Scholar
• PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108(15):1831-1838.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GH, BURGESS E, KOLLOCH RE et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. (2004) 93(8):990-996.
   PubMed Web of Science ®Google Scholar
• FLACK JM, OPARIL S, PRATT JH et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. (2003) 41(7):1148-1155.
   PubMed Web of Science ®Google Scholar
• WEINBERGER MH, WHITE WB, RUILOPE LM et al.: Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. (2005) 150(3):426-433.
   PubMed Web of Science ®Google Scholar
• KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40(2):117-123.
   PubMed Web of Science ®Google Scholar
• BURGESS ED, LACOURCIERE Y, RUILOPE-URIOSTE LM et al.: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin. Ther. (2003) 25(9):2388-2404.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. Jama (2003) 289(19):2560-2572.
   PubMed Web of Science ®Google Scholar
• OUZAN J, PERAULT C, LINCOFF AM, CARRE E, MERTES M: The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. (2002) 15(4 Pt 1):333-339.
   PubMed Web of Science ®Google Scholar
• NISHIZAKA MK, ZAMAN MA, CALHOUN DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. (2003) 16(11 Pt 1):925-930.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341(10):709-717.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348(14):1309-1321.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M, BUCKALEW JV, MARTINEZ F et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am. J. Hypertens. (2002) 15(1):A24.
   PubMed Web of Science ®Google Scholar
• KEIDAR S, KAPLAN M, PAVLOTZKY E et al.: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation (2004) 109(18):2213-2220.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, DUQUAINE D, KING S, PITT B, PATEL P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation (2002) 105(18):2212-2216.
   PubMed Web of Science ®Google Scholar
• KEIDAR S, HAYEK T, KAPLAN M et al.: Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. (2003) 41(6):955-963.
   Google Scholar
• TAKAI S, JIN D, MURAMATSU M et al.: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension (2005) 46(5):1135-1139.
   Google Scholar
• SUZUKI J, IWAI M, MOGI M et al.: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. (2006) 26(4):917-921.
   Google Scholar
• YOUNG WF Jr: Primary aldosteronism treatment options. Growth Horm. IGF Res. (2003) 13 (Suppl. A):S102-S108.
   Google Scholar
• PALMER BF: Pathogenesis of ascites and renal salt retention in cirrhosis. J. Investig. Med. (1999) 47(5):183-202.
   Google Scholar
• JADHAV PK, MATTHEWS DP, GREEN J et al.: Discovery of orally bioavailable, non-steroidal mineralo- corticoid receptor antagonist: a tale of three platforms. 231st American Chemical Society National Meeting. Altanta (2006) MEDI 179.
   Google Scholar
• NEEL DA, BROWN ML, LANDER PA et al.: 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15(10):2553-2557.
   PubMed Web of Science ®Google Scholar